SaifM. “MM-398 Achieves Primary Endpoint of Overall Survival in Phase III Study in Patients With Gemcitabine Refractory Metastatic Pancreatic Cancer”. JOP. Journal of the Pancreas, Vol. 15, no. 3, May 2014, pp. 278-9, doi:10.6092/1590-8577/2507.